每经AI快讯，仙乐健康（SZ 300791，收盘价：23.33元）10月9日晚间发布公告称，仙乐健康科技股份 有限公司及公司子公司在2025年第三季度取得4项发明专利证书、1项保健食品注册证书和22项保健食品 备案凭证。 截至发稿，仙乐健康市值为72亿元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 曾健辉） 2025年1至6月份，仙乐健康的营业收入构成为：软胶囊占比46.38%，软糖占比25.31%，片剂占比 9.26%，功能饮品占比5.42%，硬胶囊占比5.31%。 ...

Core Viewpoint - The article reports on the compliance inspection results of five pharmaceutical manufacturing companies in Xi'an, China, conducted by the Shaanxi Provincial Drug Supervision Administration, confirming their adherence to drug production quality management standards [2] Group 1: Company Inspection Results - Xi'an Jingxi Shuanghe Pharmaceutical Co., Ltd. passed the inspection for large-volume injection and washing agents, with the inspection conducted from July 7 to July 11, 2025 [2] - Shaanxi Jiuzhou Pharmaceutical Co., Ltd. passed the inspection for oral solid preparations, specifically Olaparib tablets (150mg), from August 5 to August 8, 2025 [2] - Xi'an Yuanda Detian Pharmaceutical Co., Ltd. passed the inspection for lyophilized powder injections and entrusted production of injection use Yanhuning, from July 15 to July 18, 2025 [2] - Xi'an Hanfeng Pharmaceutical Co., Ltd. passed the inspection for tablets and hard capsules, with the inspection date on September 23, 2025 [2] Group 2: Inspection Scope and Compliance - The inspections covered various production lines and workshops, ensuring compliance with the Drug Production Quality Management Standards [2] - The inspections were conducted in accordance with multiple regulatory frameworks, including the Drug Administration Law and related management measures [2]

Group 1 - The core point of the article is that Xianle Health announced the termination of its long-term employee stock ownership plan during a board meeting held on September 26, 2025 [1] - For the first half of 2025, Xianle Health's revenue composition was as follows: soft capsules accounted for 46.38%, gummies for 25.31%, tablets for 9.26%, functional beverages for 5.42%, and hard capsules for 5.31% [1] - As of the time of reporting, Xianle Health's market capitalization was 7.4 billion yuan [1]

Company Overview - Tongrentang's stock price decreased by 2.01% on September 23, trading at 11.70 CNY per share with a market capitalization of 19.793 billion CNY [1] - The company specializes in the research, production, and sales of dietary nutritional supplements, with revenue composition as follows: Others 38.02%, Capsules 27.84%, Tablets 20.38%, Powders 13.76% [1] Financial Performance - For the first half of 2025, Tongrentang reported a revenue of 3.532 billion CNY, a year-on-year decrease of 23.43%, and a net profit attributable to shareholders of 737 million CNY, down 17.34% year-on-year [2] - Cumulative cash dividends since the A-share listing amount to 8.321 billion CNY, with 2.429 billion CNY distributed over the last three years [3] Shareholder Information - As of June 30, 2025, the number of shareholders decreased by 4.96% to 71,200, while the average circulating shares per person increased by 5.22% to 15,869 shares [2] - Major shareholders include E Fund's ChiNext ETF, holding 24.5972 million shares, a decrease of 648,400 shares from the previous period [3]

Company Overview - Qianhong Biopharma Co., Ltd. is located in Changzhou, Jiangsu Province, established on April 30, 2003, and listed on February 18, 2011. The company specializes in the research, production, and sales of various pharmaceutical products, including lyophilized powder, lyophilized powder injections (including anti-tumor drugs), small-volume injections, tablets, hard capsules, granules, and raw materials [2]. Financial Performance - For the first half of 2025, Qianhong Biopharma achieved operating revenue of 862 million yuan, representing a year-on-year growth of 0.72%. The net profit attributable to the parent company was 258 million yuan, showing a significant year-on-year increase of 41.17% [2]. - The company has distributed a total of 1.862 billion yuan in dividends since its A-share listing, with 453 million yuan distributed over the past three years [3]. Stock Performance - As of September 23, Qianhong Biopharma's stock price was 9.38 yuan per share, with a market capitalization of 12.005 billion yuan. The stock has increased by 54.20% year-to-date but has seen a decline of 5.44% over the past five trading days and 12.42% over the past 20 days [1]. - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on August 7, where it recorded a net purchase of 10.2288 million yuan [1]. Shareholder Information - As of June 30, 2025, Qianhong Biopharma had 72,800 shareholders, an increase of 27.00% from the previous period. The average circulating shares per person decreased by 22.62% to 12,934 shares [2]. - Among the top ten circulating shareholders, Hong Kong Central Clearing Limited is the fourth largest, holding 29.1651 million shares, a decrease of 11.9864 million shares from the previous period [3]. Business Segments - The company's main business revenue composition includes 62.97% from formulation series and 36.70% from raw material series, with other contributions at 0.33% [2]. - Qianhong Biopharma operates within the pharmaceutical and biological industry, specifically in the chemical pharmaceutical sector, and is involved in various concept sectors such as heparin, ursodeoxycholic acid, antigen detection, medical devices, and biomedicine [2].

Group 1 - The stock price of Qianhong Biopharma fell by 2.05% on September 19, closing at 9.54 CNY per share, with a trading volume of 142 million CNY and a turnover rate of 1.56%, resulting in a total market capitalization of 12.209 billion CNY [1] - Year-to-date, Qianhong Biopharma's stock price has increased by 56.83%, but it has seen a decline of 5.36% over the last five trading days and 12.48% over the last 20 days [1] - The company has appeared on the "Dragon and Tiger List" seven times this year, with the most recent appearance on August 7, where it recorded a net purchase of 10.2288 million CNY [1] Group 2 - Qianhong Biopharma, established on April 30, 2003, and listed on February 18, 2011, is located in Changzhou, Jiangsu Province, and specializes in the production and sales of various pharmaceutical products, including lyophilized powder and injections [2] - The company's main business revenue composition includes 62.97% from formulations and 36.70% from raw materials, with other sources contributing 0.33% [2] - As of June 30, 2025, Qianhong Biopharma reported a revenue of 862 million CNY, a year-on-year increase of 0.72%, and a net profit attributable to shareholders of 258 million CNY, reflecting a growth of 41.17% [2] Group 3 - Since its A-share listing, Qianhong Biopharma has distributed a total of 1.862 billion CNY in dividends, with 453 million CNY distributed over the past three years [3] - As of June 30, 2025, the top ten circulating shareholders include Hong Kong Central Clearing Limited, which holds 29.1651 million shares, a decrease of 11.9864 million shares from the previous period [3]

Core Insights - Shanghai Kaibao's stock price increased by 0.16% on September 17, with a trading volume of 249 million yuan [1] - The company reported a financing net purchase of 10.52 million yuan on the same day, with a total financing and securities balance of 372 million yuan [1] - As of June 30, 2025, Shanghai Kaibao's revenue decreased by 27.08% year-on-year, while net profit fell by 14.20% [2] Financing and Securities - On September 17, Shanghai Kaibao had a financing buy amount of 34.43 million yuan, with a current financing balance of 371 million yuan, representing 5.62% of its market capitalization [1] - The financing balance is above the 90th percentile of the past year, indicating a high level of financing activity [1] - The company had a securities lending balance of 1.0181 million yuan, with a lending volume of 16,160 shares, also above the 80th percentile of the past year [1] Shareholder and Dividend Information - As of June 30, 2025, the number of shareholders decreased by 3.91% to 52,500, while the average circulating shares per person increased by 4.06% to 17,463 shares [2] - Since its A-share listing, Shanghai Kaibao has distributed a total of 1.521 billion yuan in dividends, with 272 million yuan distributed over the last three years [2] - The top ten circulating shareholders include significant institutional investors, with changes in holdings noted for several ETFs [2]

Core Viewpoint - The company Zhaoli Pharmaceutical announced that its digital workshop for solid pharmaceutical preparations is expected to be operational by the end of the year, which will meet the demand for capsule and tablet products [1] Group 1 - The digital workshop will enhance the production capabilities of the company [1] - The workshop aims to improve efficiency and quality in the manufacturing process of solid dosage forms [1] - The initiative aligns with industry trends towards digitalization in pharmaceutical manufacturing [1]

Core Viewpoint - Xianle Health's stock price has shown a year-to-date increase of 26.74%, indicating positive market performance despite a recent decline of 2.07% on September 12 [2][1]. Company Overview - Xianle Health Technology Co., Ltd. was established on August 16, 1993, and went public on September 25, 2019. The company is based in Shantou, Guangdong Province and specializes in the research, production, sales, and technical services of nutritional health products [2]. - The company's revenue composition includes soft capsules (46.38%), gummies (25.31%), tablets (9.26%), beverages (5.42%), hard capsules (5.31%), powders (4.45%), and other forms (3.22%) [2]. Financial Performance - For the first half of 2025, Xianle Health reported a revenue of 2.042 billion yuan, representing a year-on-year growth of 2.57%. The net profit attributable to shareholders was 161 million yuan, reflecting a growth of 4.30% compared to the previous year [2]. - Since its A-share listing, Xianle Health has distributed a total of 583 million yuan in dividends, with 415 million yuan distributed over the past three years [3]. Shareholder Information - As of June 30, 2025, the number of shareholders for Xianle Health reached 12,100, an increase of 9.08% from the previous period. The average number of circulating shares per shareholder was 21,172, up by 19.00% [2]. - Notable institutional shareholders include招商产业精选股票A (holding 2.2 million shares) and东方红核心价值混合A (holding 1.8095 million shares), both of which are new entrants among the top ten circulating shareholders [3].

2025 年 9 月 5 日投资者关系活动记录表 仙乐健康科技股份有限公司 投资者关系活动记录表 证券代码：300791 证券简称：仙乐健康 证券代码：123113 证券简称：仙乐转债 仙乐健康科技股份有限公司 编号： 2025-004 投资者关系 活动类别 □特定对象调研 □分析师会议 □媒体采访 ■业绩说明会 □新闻发布会 □路演活动 □现场参观 □其他（ ） 参与单位名称 及人员姓名 投资者网上提问 时间 2025 年 9 月 5 日 15:30-17:30 方式 公司通过"全景·路演天下"（https://rs.p5w.net/）采用网络远程的方式 召开业绩说明会 上市公司 接待人员姓名 公司董事长兼总经理：林培青 副总经理、代理财务负责人：郑丽群 副总经理、董事会秘书：刘若阳 独立董事：高见 保荐代表人：刘兴德 投资者关系活 动主要内容介 问题：美洲市场收入同比增长 4.26，其中出口业务克服关税影响同增 7.4，请问公司是如何应对关税问题，未来在美洲市场有什么具体的拓展 1 仙乐健康科技股份有限公司 投资者关系活动记录表 绍 计划 答：公司积极采取多种手段控制对等关税对美出口业务的影响：首先，公 ...